'Living Fossil' Fish Species Once Thought Extinct for 70 Million Years Photographed in Rare Sighting
A species of coelacanth, a fish that dates back to before the dinosaurs, has been photographed in Indonesia for the first time.
The Indonesian coelacanth (Latimeria menadoensis), once considered extinct for 70 million years, was photographed in the Maluku Archipelago, Indonesia, and marks the first time the coelacanth species has been caught on camera in Indonesian waters. The rare fish was spotted by divers searching approximately 475 feet below the ocean's surface. Alexis Chappuis, a marine biologist with UNSEEN Expeditions, is credited with the sighting, per Swiss luxury watchmaking company Blancpain, which helped fund the expedition.
Chappuis overcame the challenge of deep mixed-gas diving, which has led many divers to experience decompression sickness, sometimes referred to as "the bends," per the U.S. Centers for Disease Control and Prevention (CDC).
Related: 5-Foot-Long 'Cannibal Fish' with 'Sharp Fang-Like Teeth' Washes Up in Rare Sighting on Oregon Beach
The expedition was a collaboration between international organizations and Udayana University in Bali.
"The coelacanth, often mistakenly called a 'living fossil' or 'dinosaur fish' had been known from fossils dated back to more than 400 million years – way before dinosaurs – and was thought to be extinct until 1938, when a specimen was discovered in a fishing net off the coast of South Africa. This marked one of the biggest natural history discoveries of the 20th century," Blancpain's release read.
Little was heard from coelacanths after the 1938 find until 2013, when Laurent Ballesta documented wild coelacanths in Sodwana Bay, off the east coast of South Africa. This reportedly marked the first time a coelacanth was photographed in its natural habitat.
Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories.
The sighting was of the other extant coelacanth species, the West Indian Ocean Latimeria chalumnae. Before Ballesta's sighting, some scientists believed the fish died with the extinction of dinosaurs, BBC reports.
"Blancpain is proud to support bold scientific projects that lead, inspire, and have a positive impact on global marine conservation," Blancpain CEO Marc A. Hayek said. "Following Laurent Ballesta's milestone in 2013, we are very proud of this discovery, which reaffirms our commitment to these efforts for more than two decades."
Related: Creepy Fish Species Invades U.S. Waters, Now Residents are Being Told to Kill the Creature on Sight
Blancpain created the Fifty Fathoms, a watch widely used by underwater divers, in 1953.
Coelacanths are highly sensitive to their environment, so the exact location of Chappuis' discovery will remain confidential until further environmental protections are in place.
"This discovery highlights the rich biodiversity of North Maluku and underscores the urgency of further exploration and conservation of the mesophotic zone," Dr. Gino Valentino Limmon, a researcher at Pattimura University and expedition partner, said in a statement.
Read the original article on People
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
3 days ago
- Business Wire
Debiopharm and Alkyon Therapeutics Announce Research Collaboration to Advance the Next Generation of Radioligand Therapies
MARTIGNY, Switzerland & LAUSANNE, Switzerland & SAN DIEGO--(BUSINESS WIRE)--Debiopharm ( a privately-owned Swiss biopharmaceutical company committed to establishing tomorrow's standard of care to cure cancer and infectious diseases and Alkyon Therapeutics, Inc., a biotechnology company pioneering precision-targeted therapies, today announced the signing of a co-research agreement to evaluate the feasibility of developing targeted radioligand therapies (RLTs) using Debiopharm's proprietary AbYlink™ conjugation technology for Alkyon's modular antibody platform directed against undisclosed tumor-associated antigens. This collaboration marks a promising step toward a new generation of RLTs designed to deliver potent radiation targeted directly to cancer cells while minimizing damage to healthy tissues. By leveraging the unique strengths of both platforms, the goal is to create more effective, better-tolerated cancer treatments that improve patient quality of life and expand therapeutic options for difficult-to-treat tumors. AbYLink™ technology enables regio-selective lysine conjugation, ensuring the radioligand avoids the target binding site and facilitating streamlined, consistent manufacturing. 'We're intrigued to explore the potential of applying AbYlink™ conjugation technology to the radio-oncology field,' expressed Frederic Levy, Chief Scientific Officer, Debiopharm. 'Leveraging our innovative conjugation platform with Alkyon's engineered antibody scaffolds could open new possibilities for next-generation radiopharmaceuticals with enhanced precision and therapeutic impact.' 'This collaboration reflects our shared commitment to expanding the potential of radioligand therapies,' said Benjamin Titz, Co-Founder and CEO of Alkyon Therapeutics. 'By applying AbYlink™ to our specialized antibody scaffolds and targeting strategies tailored to the unique architecture of solid tumors, we aim to unlock new therapeutic possibilities and advance care for patients with difficult-to-treat solid tumors.' About AbYlink™ AbYlink™ is a versatile and rapid regio-selective chemical conjugation technology for use in preparing diagnostic or therapeutic conjugates. This one-step method results in stable conjugation at defined and invariable sites on the Fc domain of an antibody or the like, with no impact on antigen-binding regions. It enables a seamless and reproducible conjugation of payloads (e.g., a chelator for radiolabeling, a fluorescent dye or a drug) to antibodies or ADCs. The universal applicability of the technology has been demonstrated for various antibody isotypes and payloads. About Alkyon Therapeutics, Inc. Alkyon Therapeutics, Inc. (AlkyonTx™) is a biotechnology company developing next-generation radioligand therapies (RLTs) for solid tumors. By combining precision-engineered antibodies with advanced radiochemistry and dosimetry technologies, Alkyon aims to overcome barriers such as immune exclusion and drug resistance in difficult-to-treat cancers. Its modular platform supports monotherapies, bispecifics, and rational combinations designed to enable differentiated clinical benefit and scalable product development. Debiopharm's commitment to patients Debiopharm aims to develop innovative therapies that target high unmet medical needs primarily in oncology and bacterial infections. Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds and technologies for in-licensing, clinically demonstrate their safety and efficacy, and then hand stewardship to large pharmaceutical commercialization partners to maximize patient access globally. For more information, please visit
Yahoo
4 days ago
- Yahoo
"STRONGER TOGETHER": SWITZERLAND CHAMPIONS INTERNATIONAL PARTNERSHIPS AS KEY TO ACCELERATED INNOVATION", ONCE AGAIN SWITZERLAND IS SHOWCASING ITS BIOTECH EXCELLENCE AT BIO INTERNATIONAL IN BOSTON 16-19 JUNE, 2025
Swiss biotech excellence returns to BIO 2025 in Boston, where Switzerland Global Enterprise presents 45 cutting-edge Swiss companies at the SWISS BIOTECH pavilion, booth #2345, showcasing the country's healthcare innovation leadership. ZURICH, June 11, 2025 /PRNewswire/ -- The represented biotech companies primarily focus on therapeutics development across oncology, respiratory diseases, rare diseases, and CNS disorders, alongside advanced drug discovery technologies including 3D microtissues, transcriptomics, and novel delivery systems. Switzerland's biotech sector thrives on international collaboration, with 80% of Swiss biotech patents resulting from partnerships rather than competition. The country leverages its diverse talent pool and takes leadership roles in global initiatives like the 47-country Eureka network (chaired by Innosuisse) and the Access Consortium for joint regulatory approvals. This collaborative approach spans from research to market access, positioning Switzerland as a valuable global partner in solving health care challenges. In short: "Switzerland's collaborative model offers a compelling counterproposal to 'me first' approaches, fostering international knowledge exchange to become stronger, faster and smarter together", says Michael Altorfer CEO, Swiss Biotech Association. Switzerland Global Enterprise with its partner Swissnex in Boston and New York will be hosting a Swiss "Wine and Cheese" reception on Tuesday June 17th from 5pm to 6:30pm at the Swiss Pavilion, booth #2345. Alithea Genomics Global leader in scalable transcriptomics solutions for screening applications. Altamira Therapeutics AG Developing and supplying peptide-based nanoparticle technologies for efficient RNA delivery to extrahepatic tissues (xPhore™ platform). BioAlps Association Acts as a life sciences cluster promoting networking and collaboration in the BioAlps community. Bioengineering AG Provides solutions in bioprocess engineering, ranging from development to production scale. Biopôle SA Operates a life sciences campus that supports innovation and development in the healthcare and biotech sectors. Bioscibex Providing cutting-edge bioreactor technologies that simplify and automate cell-based therapies. BioVersys AG Promotes Switzerland as a prime location for business and investment. CDR-Life AG Developing highly specific antibody therapeutics to target intracellular proteins presented on the major histocompatibility complex (MHC). EM Microelectronic Semiconductor manufacturer specialized in the design and production of ultra-low power, low voltage integrated circuits (IC) for battery-operated and field-powered applications. Enantios AG Utilizes cutting edge technology to analyze chiral molecules and biologics. EPIC Suisse Property Management GmbH Offers comprehensive property management services across Switzerland. Ibex Therapeutics SA Developing a patented oral topical therapy to cure and prevent oral mucositis and oral candidiasis. InSphero AG Develops and produces 3D microtissues for drug discovery and toxicity testing. KPMG Offers audit, tax, and advisory services to help organizations. Limula SA They provide a unique platform technology that enable manufacturing of clinical-grade cell products at scale, through automation and standardization. Molecular Partners AG Develops a new class of custom-built protein therapeutics known as DARPin® molecules. Ninsun Biotech Revolutionizing the marking of cancer stem cells by offering a specific biomarker for several cancers, including lung, breast and colon Novavax Proven vaccine technology, focused on developing R&D assets and establishing partnerships to leverage the value of the technology to help protect health. NXI Therapeutics AG Developing selective immunomodulators, which regulate T cell immune responses that play a key role in graft rejection and autoimmunity, while leaving the protective responses against infections and vaccination intact. ObelysQ SA Quality assurance consulting firm offering tailored solutions to the pharma industry aiming at enhancing compliance and improving processes in the execution of clinical trials. OM Pharma Engages in the research, development, and marketing of medicines in respiratory and vascular diseases. PDC Therapeutics Focuses on developing precision drugs for the treatment of severe and rare diseases. Perseo Pharma AG Breaking new ground in the treatment of metabolic diseases Polaroid Therapeutics Proprietary technology represents a significant advancement in antimicrobial therapies, setting a new standard in the industry. Superlab Suisse AG Provides high-tech laboratory services and research facilities for life sciences companies. Tigermed Swiss SA Offers clinical trial management and pharmaceutical consulting services. Venture Valuation Inc. Specializes in the assessment and valuation of growth companies in the life sciences and technology sectors. Cellvie Dedicated to advancing mitochondrial transplantation therapy to treat acute and chronic degenerative diseases. FluoSphera Provides high-throughput screening services using innovative fluorescence-based technologies. Nagi Bioscience Develops the first Organism-on-Chip technology for automated and ethical testing of drugs and chemicals. REM Analytics SA Specializes in microbiome analytics and solutions for healthcare and agricultural applications. Synendos Therapeutics AG Focuses on the development of breakthrough therapies for the treatment of central nervous system disorders. Vandria Offers digital solutions to enhance the efficiency and effectiveness of healthcare and medical management. Alpha Onco Engages in the development of innovative oncology treatments. BioArk Provides infrastructure and support for startups and established companies in the life sciences sector. Ceidos SA Specializes in virtual reality solutions, primarily for therapeutic and rehabilitation applications. Excellgene Produces biopharmaceuticals using advanced cell line engineering and protein production technologies. Immunskills Offers workshops and training in immunotherapy and biological production. Novochizol SA Develops chitosan-based formulations to enhance the delivery of biopharmaceuticals. Orio Therapeutics Specializes in developing therapies for respiratory diseases. SETI / Canton VS Supports economic development in Valais, particularly in the sectors of technology, education, and innovation. Stämm Biotech Works on bioprocesses that utilize human stem cells for regenerative medicine. Swiss Biotech Center Provides laboratory services, R&D, and consulting to foster innovation in biotechnology. ten23 health Valais Ltd. Offers services in drug development and manufacturing, with a focus on sustainable practices. Ymmunobio AG Ymmunobio AG is a preclinical stage biotechnology company developing a novel class of immune oncology therapeutic antibodies. The SWISS BIOTECH companies will be available for media and partner interviews the entire week. Media Contacts Partnerships & Business Development Lisette Müry Karine J. Wittmer E: E. Trade Fairs Foreign Direct Investment Export Promotion & Global Network Trade Commissioner Bettina Thomas Sean Powers E: Bthomas@ E: About Switzerland Global EnterpriseSwitzerland Global Enterprise (S-GE) is the official Swiss organization for export and investment promotion with around 200 employees at locations throughout Switzerland and overseas. S-GE supports Swiss SMEs in their international business and helps innovative foreign companies to settle in Switzerland. In doing so, we rely on a unique network of national and international partners. This allows us to create added value for our customers and prosperity for Switzerland. As a non-profit organization, we provide a public service for our clients on behalf of the Swiss Confederation (State Secretariat for Economic Affairs SECO) and the cantons. We operate our 27 offices, the so-called Swiss Business Hubs, and Trade Points, in 31 countries jointly with the Federal Department of Foreign Affairs (FDFA). Thanks to our global network of partners, we also support our customers in many other countries. View original content to download multimedia: SOURCE Swiss Business Hub USA Sign in to access your portfolio
Yahoo
07-06-2025
- Yahoo
Mountains are among the planet's most beautiful places. They're also becoming the deadliest
Jan Beutel was half-watching a live stream of Kleines Nesthorn, a mountain peak in the Swiss Alps, when he realized its cacophony of creaks and rumbles was getting louder. He dropped his work, turned up the sound and found himself unable to look away. 'The whole screen exploded,' he said. Beutel, a computer engineer specializing in mountain monitoring, had just witnessed a glacier collapse. On May 28, an avalanche of millions of tons of ice and rock barreled down the slope, burying Blatten, a centuries-old village nestled in the valley below. Local authorities had already evacuated the village after parts of the mountain had crumbled onto the glacier; a 64-year old man believed to have stayed remains missing. But no one expected an event of this magnitude. Successive rock avalanches onto the glacier increased the pressure on the ice, causing it to melt faster and the glacier to accelerate, eventually destabilizing it and pushing it from its bed. The collapse was sudden, violent and catastrophic. 'This one just left no moment to catch a breath,' Beutel said. The underlying causes will take time to unravel. A collapse of this magnitude would have been set in motion by geological factors going back decades at least, said Matthias Huss, a glaciologist at the Swiss university ETH Zürich. But it's 'likely climate change is involved,' he said, as warming temperatures melt the ice that holds mountains together. It's a problem affecting mountains across the planet. People have long been fascinated with mountains for their dramatic beauty. Some make their homes beneath them — around 1 billion live in mountain communities — others are drawn by adventure, the challenge of conquering peaks. These majestic landscapes have always been dangerous, but as the world warms, they are becoming much more unpredictable and much deadlier. 'We do not fully understand the hazard at the moment, nor how the dangers are changing with climate change,' said David Petley, an Earth scientist at the University of Hull in England. Snowy and icy mountains are inherently sensitive to climate change. Very high mountains are etched with fractures filled with ice — called permafrost — which glues them together. As the permafrost thaws, mountains can become destabilized. 'We are seeing more large rock slope collapses in many mountains as a result,' Petley told CNN. Glaciers are also melting at a terrifyingly rapid rate, especially in regions such as the Alps and the Andes, which face the possibility of a glacier-free future. As these rivers of ancient ice disappear, they expose mountain faces, causing more rocks to fall. There have been several big collapses in the Alps in recent years as ice melts and permafrost thaws. In July 2022, about 64,000 tons of water, rock and ice broke off from the Marmolada Glacier in northern Italy after unusually hot weather caused massive melting. The subsequent ice avalanche killed 11 people hiking a popular trail. In 2023, the peak of Fluchthorn, a mountain on the border between Switzerland and Austria, collapsed as permafrost thawed, sending more than 100,000 cubic meters of rock into the valley below. 'This really seems to be something new. There seems to be a trend in such big events in high mountain areas,' Huss said. Melting glaciers can also form lakes, which can become so full that they burst their banks, sending water and debris cascading down mountainsides. In 2023, a permafrost landslide caused a large glacial lake in Sikkim, India, to break its banks, causing a catastrophic deluge that killed at least 55 people. Last year, a glacial lake outburst caused destructive flooding in Juneau, Alaska — a now regular occurrence for the city. After two years in a row of destructive glacial flooding, Juneau is scrambling to erect temporary flood barriers ahead of the next melting season, the Anchorage Daily News reported this week. As well as melting ice, there's another hazard destabilizing mountains: rain. Extreme precipitation is increasingly falling on mountains as rain instead of snow, said Mohammed Ombadi, an assistant professor at the University of Michigan College of Engineering. His research shows every 1 degree Celsius of global warming increases extreme rainfall events by 15%. This pushes up the risks of flooding, landslides and soil erosion. Northern Hemisphere mountains will become 'hotspots' for extreme rain, Ombadi said. Heavy rainfall this month in Sikkim, a Himalayan state in northern India, triggered a series of landslides, killing at least three people. Images show deep muddy scars carved into the mountain, with buildings and trees obliterated. Scientists do have tools to monitor mountains and warn communities. 'There are fantastic instruments that can predict quite accurately when a rock mass (or) ice mass is going to come down,' Huss said. The difficulty is knowing where to look when a landscape is constantly changing in unpredictable ways. 'This is what climate change actually does… there are more new and previously unrecognized situations,' Huss said. These are particularly hard to deal with in developing countries, which don't have the resources for extensive monitoring. Scientists say the only way to reduce the impact of the climate crisis on mountains is to bring down global temperatures, but some changes are already locked in. 'Even if we manage to stabilize the climate right now, (glaciers) will continue to retreat significantly,' Huss said. Almost 40% of the world's glaciers are already doomed, according to a new study. 'We could have maybe avoided most of (the negative impacts) if we had acted 50 years ago and brought down CO2 emissions. But we failed,' Huss added. The consequences are hitting as the numbers of people living in and visiting mountains increases. 'We're just more exposed than we used to be,' he said. Ludovic Ravanel, an Alpine climber and geomorphologist who focuses on mountains' response to global warming, has a front line view of the increasing dangers of these landscapes. Mountains are the 'most convincing' hotspots of climate change, he told CNN. When he's focused on the science, he keeps his emotions at arm's length. But as a father, and a mountaineer, it hits him. 'I see just how critical the situation is. And even then, we're only at the very beginning.'